These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33612190)

  • 41. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States.
    Paschen-Wolff MM; Velasquez R; Aydinoglo N; Campbell ANC
    J Subst Abuse Treat; 2022 Sep; 140():108828. PubMed ID: 35749919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.
    Chatterjee A; Baker T; Rudorf M; Walt G; Stotz C; Martin A; Kinnard EN; McAlearney AS; Bosak J; Medley B; Pinkhover A; Taylor JL; Samet JH; Lunze K
    J Subst Use Addict Treat; 2024 Apr; 159():209272. PubMed ID: 38128649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using machine learning to study the effect of medication adherence in Opioid Use Disorder.
    Warren D; Marashi A; Siddiqui A; Eijaz AA; Pradhan P; Lim D; Call G; Dras M
    PLoS One; 2022; 17(12):e0278988. PubMed ID: 36520864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "I think we're getting better but we're still not there": Provider-based stigma and perceived barriers to care for people who use opioids (PWUO).
    McLean K; Murphy J; Kruis N
    J Subst Use Addict Treat; 2024 Apr; 159():209270. PubMed ID: 38103831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
    Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
    J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
    Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
    J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Perceptions of medications, program settings, and drug use histories among individuals engaged in treatment for opioid use disorder.
    Scherzer C; Jiménez Muñoz P; Ramsey S; Carey KB; Ranney ML; Clark S; Rich J; Langdon KJ
    J Addict Dis; 2024; 42(1):24-32. PubMed ID: 36325942
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder.
    Gopaldas M; Wenzel K; Campbell ANC; Jalali A; Fishman M; Rotrosen J; Nunes EV; Murphy SM
    Psychiatr Serv; 2023 Dec; 74(12):1227-1233. PubMed ID: 37337675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 55. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
    Michener PS; Evans EA; Ferguson WJ; Friedmann PD
    Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Knowledge, experiences, and perceptions of medications for opioid use disorder among Black Kentuckians.
    Wheeler PB; Miller-Roenigk B; Jester J; Stevens-Watkins D
    Ann Med; 2024 Dec; 56(1):2322051. PubMed ID: 38442301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Stigma on Clinician Training for Opioid Use Disorder Care: A Qualitative Study in a Primary Care Learning Collaborative.
    Klusaritz H; Bilger A; Paterson E; Summers C; Barg FK; Cronholm PF; Saine ME; Sochalski J; Doubeni CA
    Ann Fam Med; 2023 Feb; 21(Suppl 2):S31-S38. PubMed ID: 36849482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System.
    Grella CE; Ostile E; Scott CK; Dennis M; Carnavale J
    Int J Drug Policy; 2020 Jul; 81():102768. PubMed ID: 32446130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.